Status: Recruiting
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of \[18F\]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
Participants needed: 316
Trial details
Phase: Phase 3Age: 50+Biological sex: AllType: InterventionalSponsor: JYAMS PET Research & Development LimitedUpdated: Feb 20, 2026Locations: 2
Eligibility criteria
Subjects must be able to understand and voluntarily sign a written informed cons... [+4]
Specific clinical phenotypes of atypical AD as defined in the 2014 IWG-2 criteri... [+12]